排序方式: 共有3条查询结果,搜索用时 15 毫秒
1
1.
Leask A 《Journal of cell communication and signaling》2012,6(1):59-60
There is no therapy for chronic fibroproliferative diseases, in spite of the fact that current health statistics suggest that
these (which include cardiovascular disease, pulmonary fibrosis, diabetic nephropathy, liver cirrhosis and systemic sclerosis)
have been estimated to cause approximately 45% of the deaths in the developed world. Recently, many studies have shown that
mitogen activated protein kinases (MAPKs) are activated in response to fibrogenic agents and contribute to the formation and
function of the myofibroblast, the critical cell type responsible for excessive scarring. A recent report by Madala and colleagues
(Am J Respir Cell Mol Biol, 2011) has provided a proof-of-concept study showing that the specific MEK inhibitor ARRY-142886 (ARRY) can both suppress the progression
of fibrosis and reverse an animal model of lung fibrosis. Thus MEK inhibition could be a valuable method to treat lung fibrosis. 相似文献
2.
Katherine Thompson Hannah Murphy-Marshman Andrew Leask 《Journal of cell communication and signaling》2014,8(1):59-63
The potent profibrotic cytokine TGFβ induces connective tissue growth factor (CCN2/CTGF) is induced in fibroblasts in a fashion sensitive to SB-431542, a specific pharmacological inhibitor of TGFβ type I receptor (ALK5). In several cell types, TGFβ induces CCN1 but suppresses CCN3, which opposes CCN1/CCN2 activities. However, whether SB-431542 alters TGFβ-induced CCN1 or CCN3 in human foreskin fibroblasts in unclear. Here we show that TGFβ induces CCN1 but suppresses CCN3 expression in human foreskin fibroblasts in a SB-431542-sensitive fashion. These results emphasize that CCN1/CCN2 and CCN3 are reciprocally regulated and support the notion that blocking ALK5 or addition of CCN3 may be useful anti-fibrotic approaches. 相似文献
3.
1